10x Science, a startup focused on drug candidate characterization, has secured a seed funding of $4.8 million, with major contributions from Initialized Capital and Y Combinator. Founded in December 2025, the company aims to address the challenges of evaluating numerous potential treatments produced by AI models, particularly in biopharma.
The founders, including chemical biologist David Roberts, and biologist Andrew Reiter, encountered significant hurdles while studying at Stanford under Nobel laureate Dr. Carolyn Bertozzi. They recognized the need for precise molecular understanding in drug development. Their platform utilizes sophisticated algorithms combined with AI to analyze complex data generated through mass spectrometry, a crucial technique for determining molecular structure.
As AI continues to drive innovation in drug discovery, 10x Science's goal is to streamline the characterization process, ensuring that candidates can effectively move from prediction to practical application. The insights derived from their platform are intended to facilitate compliance with regulatory standards in drug development.